Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• A specific biomarker in the tumour must be confirmed as eligible for this trial.
• Tumour tissue samples collected before any treatment, along with a pathology report, must be available — ideally as a preserved tissue block, or as at least 10–15 prepared slides.
• A person must have a performance status score of 0 or 1 on the ECOG scale, meaning they are fully active or have only minor restrictions on physical activity (confirm with trial site).
• A person must have non-small cell lung cancer (NSCLC) that has been confirmed by laboratory testing and has either spread to other parts of the body or cannot be removed by surgery, and is not suitable for curative surgery or radiation combined with chemotherapy.
• A person must not have received any prior systemic (whole-body) treatment for advanced or metastatic NSCLC.
• A person must have measurable disease according to standard imaging criteria. For one specific group in the trial (Cohort D), measurable tumours in the brain that are small, not causing symptoms, and not requiring immediate local treatment are also required (confirm with trial site).

Who may not be able to join:

• People whose cancer is driven by a second known genetic mutation for which a targeted treatment already exists.
• People whose NSCLC is of the squamous cell type.
• People in Cohorts A, B, or C who have brain metastases that are causing symptoms, have not been treated, or are actively growing.
• People who have previously been treated with a KRAS G12C inhibitor drug.
• People with a known allergy to divarasib or pembrolizumab; or, for Cohort B only, a known allergy to pemetrexed, carboplatin, or cisplatin.
• People with a history of certain lung conditions, including idiopathic pulmonary fibrosis, organising pneumonia, or drug-induced lung inflammation, or who currently have active lung inflammation, active tuberculosis, or a significant heart condition within the past 3 months.
• People who have had another type of cancer within the past 5 years — with some exceptions for certain low-risk cancers such as early-stage cervical, skin, prostate, or breast conditions (confirm with trial site for specific exceptions).
• People with uncontrolled cancer-related pain, fluid build-up around the lungs or heart, or abdominal fluid that regularly needs draining, or uncontrolled high calcium levels in the blood.
• People with a medical condition that means they absolutely cannot take corticosteroids (a type of anti-inflammatory medicine).
• People who are unable or unwilling to take preventive medicines such as corticosteroids, anti-nausea medicines, folic acid, or vitamin B12 supplements.
• People with brain metastases for whom complete surgical removal is considered the most appropriate treatment option.

Important: Always verify eligibility with the trial site directly before applying.